Xenon Pharmaceuticals (XENE) Assets (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Assets of $1.4 billion for Q1 2026, up 86.58% year-over-year from $743.3 million in Q1 2025, and up 119.03% quarter-over-quarter from $633.2 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Assets (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Assets for 14 consecutive years, with $1.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 86.58% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 86.58% YoY), while the FY2025 annual figure was $633.2 million, down 20.67% from the prior year.
- Assets improved to $1.4 billion in Q1 2026 per XENE's latest filing, from $633.2 million in the prior quarter.
- Across five years, Assets topped out at $1.4 billion in Q1 2026 and bottomed at $558.1 million in Q1 2022.
- Historically, Assets has averaged $789.3 million across 5 years, with a median of $754.1 million in 2022.
- Annual changes were most pronounced in 2022 — Assets soared 193.9% — and 2025, when it dropped 27.28%.
- Xenon Pharmaceuticals' Assets stood at $754.1 million in 2022, then rose by 27.93% to $964.8 million in 2023, then fell by 17.27% to $798.1 million in 2024, then retreated by 20.67% to $633.2 million in 2025, then jumped by 119.03% to $1.4 billion in 2026.
- Business Quant data shows XENE's Assets at $1.4 billion in Q1 2026, $633.2 million in Q4 2025, and $607.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 1.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Bn |
| Mar 31, 2026 | 1.39 Bn |
| Dec 31, 2025 | 633.16 Mn |
| Sep 30, 2025 | 607.84 Mn |
| Jun 30, 2025 | 674.28 Mn |
| Mar 31, 2025 | 743.28 Mn |
| Dec 31, 2024 | 798.14 Mn |
| Sep 30, 2024 | 835.90 Mn |
| Jun 30, 2024 | 884.01 Mn |
| Mar 31, 2024 | 919.02 Mn |
| Dec 31, 2023 | 964.80 Mn |
| Sep 30, 2023 | 671.09 Mn |
| Jun 30, 2023 | 684.90 Mn |
| Mar 31, 2023 | 719.87 Mn |
| Dec 31, 2022 | 754.15 Mn |
| Sep 30, 2022 | 775.81 Mn |
| Jun 30, 2022 | 807.38 Mn |
| Mar 31, 2022 | 558.06 Mn |
| Dec 31, 2021 | 572.01 Mn |
| Sep 30, 2021 | 264.35 Mn |